Biotech IPOs comes roaring back, the eye is a window to the brain, will UK's sugar tax work? and other interesting reads from the past week.

Noteworthy 📰

• Amazon’s latest pharmacy push just wiped out $24 billion in market cap for healthcare giants. Link

• Here’s what’s next now that the FDA has approved a cannabis drug for seizures. Link

• The pharma industry tilt of the FDA. Link

• India is on the front line of the battle to prevent a post-antibiotic world. Link

• Biotech IPOs have come roaring back. Link

• AstraZeneca oncology biz boosted by Lynparza results. Link

• Private equity is pouring money into a dental empire. Link

Digital Health 💻

• Electronic databases play a major role in the opioid abuse crackdown. Link

• Babylon's AI passes mockup of UK's GP exam, goes head-to-head with doctors. Link

Research 🔬

• The eye's structure holds information about the health of the mind. Link

• Brain-protein structure could point way to safer prescription drugs. Link

Perspective and Opinions 📢

• Calls for a new tax on drug sales to help fund new antibiotic reward scheme. Link

• The UK has introduced a sugar tax, but will it work? Link

Deep Dive 👓

Why be a vaccine company? Just four companies — GlaxoSmithKline, Merck, Sanofi, and Pfizer — dominate the vaccine market, but the sector does offer opportunity, with more consistent revenue streams than other categories, albeit with lower margins. Link

Beyond bionics: how the future of prosthetics is redefining humanity

Interesting 🤔

A new website charts countries' readiness to deal with disease outbreaks. Link

Notable Startups 💰

Skyhawk’s innovative STAR* technology platform to discover and develop small molecules that correct mutations in RNA. Closed a new $40m equity investment.

Catalog has developed a solution to make DNA data storage commercially viable. Raised $9M in funding

NBE Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for improved cancer therapy. Raised a CHF20m Series B round.

Appello Pharmaceuticals is focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease. Completed a $10.5m Series A round.

Our Digital Times 😃